Edition:
India

vTv Therapeutics Inc (VTVT.OQ)

VTVT.OQ on NASDAQ Stock Exchange Global Market

1.57USD
22 Jun 2018
Change (% chg)

$-0.10 (-5.99%)
Prev Close
$1.67
Open
$1.80
Day's High
$1.80
Day's Low
$1.56
Volume
573,917
Avg. Vol
237,740
52-wk High
$8.37
52-wk Low
$0.65

Chart for

About

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting... (more)

Overall

Beta: --
Market Cap(Mil.): $204.09
Shares Outstanding(Mil.): 32.81
Dividend: --
Yield (%): --

Financials

BRIEF-VTV Therapeutics Announces Company Will Pre-Specify New Subgroup With The FDA

* VTV THERAPEUTICS ANNOUNCES COMPANY WILL PRE-SPECIFY NEW SUBGROUP WITH THE FDA AND REPORT PHASE 3 PART B RESULTS IN JUNE

10 May 2018

BRIEF-Vtv Therapeutics Announces Topline Results From The First Steadfast Phase 3 Study Evaluating Azeliragon In People With Mild Alzheimer's Disease

* VTV THERAPEUTICS ANNOUNCES TOPLINE RESULTS FROM THE FIRST STEADFAST PHASE 3 STUDY EVALUATING AZELIRAGON IN PEOPLE WITH MILD ALZHEIMER’S DISEASE

10 Apr 2018

BRIEF-vTv Therapeutics Says Phase 1B Study Of TTP399 For The Treatment Of Type 1 Diabetes Completed

* VTV THERAPEUTICS ANNOUNCES COMPLETION OF PHASE 1B STUDY EVALUATING TTP399 FOR THE TREATMENT OF TYPE 1 DIABETES Source text for Eikon: Further company coverage:

23 Mar 2018

BRIEF-VTV Therapeutics Reports Q4 Loss Per Share $0.44

* VTV THERAPEUTICS REPORTS 2017 FOURTH QUARTER AND FULL YEAR FINANCIAL AND OPERATIONAL RESULTS AND RECENT HIGHLIGHTS

28 Feb 2018

BRIEF-vTv Therapeutics Files For Stock Shelf Of Up To $250 Million

* VTV THERAPEUTICS INC FILES FOR STOCK SHELF OF UP TO $250 MILLION – SEC FILING‍​ Source text for Eikon: (http://bit.ly/2EUHrux) Further company coverage:

28 Feb 2018

Earnings vs. Estimates